FIL Ltd Has $2.94 Million Holdings in Verrica Pharmaceuticals Inc (VRCA)

FIL Ltd lowered its position in shares of Verrica Pharmaceuticals Inc (NASDAQ:VRCA) by 56.7% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 181,009 shares of the company’s stock after selling 236,585 shares during the period. FIL Ltd owned about 0.70% of Verrica Pharmaceuticals worth $2,941,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Kornitzer Capital Management Inc. KS bought a new position in Verrica Pharmaceuticals during the second quarter valued at about $2,905,000. Dean Capital Investments Management LLC bought a new position in shares of Verrica Pharmaceuticals in the second quarter worth about $676,000. Asymmetry Capital Management L.P. bought a new position in shares of Verrica Pharmaceuticals in the second quarter worth about $1,184,000. FMR LLC bought a new position in shares of Verrica Pharmaceuticals in the second quarter worth about $21,703,000. Finally, Fosun International Ltd bought a new position in shares of Verrica Pharmaceuticals in the second quarter worth about $15,705,000. 30.86% of the stock is owned by institutional investors and hedge funds.

In other news, Director Paul B. Manning bought 70,200 shares of the firm’s stock in a transaction that occurred on Tuesday, November 13th. The shares were acquired at an average cost of $14.15 per share, with a total value of $993,330.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Linda Palczuk bought 2,500 shares of the firm’s stock in a transaction that occurred on Monday, September 17th. The shares were purchased at an average cost of $16.52 per share, for a total transaction of $41,300.00. The disclosure for this purchase can be found here.

Separately, Zacks Investment Research upgraded Verrica Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, October 6th.

Verrica Pharmaceuticals stock opened at $12.00 on Monday. Verrica Pharmaceuticals Inc has a 52 week low of $11.10 and a 52 week high of $23.29.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its quarterly earnings data on Wednesday, November 7th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). As a group, sell-side analysts anticipate that Verrica Pharmaceuticals Inc will post -1.17 EPS for the current year.

WARNING: This news story was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.com-unik.info/2018/12/03/fil-ltd-has-2-94-million-holdings-in-verrica-pharmaceuticals-inc-vrca.html.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790.

Recommended Story: Google Finance Portfolio Tips and Tricks

Institutional Ownership by Quarter for Verrica Pharmaceuticals (NASDAQ:VRCA)

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit